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Background: Elderly patients are commonly under-represented in cancer clinical trials. The 321GO was undertaken in preparation
for a definitive phase three trial assessing different chemotherapy regimens in a frail and/or elderly population with advanced
gastroesophageal (GO) cancer.
Methods: Patients with advanced GO cancer considered unfit for conventional dose chemotherapy were randomly assigned in a
1 : 1 : 1 ratio to: epirubicin, oxaliplatin and capecitabine (EOX); oxaliplatin and capecitabine (OX); and capecitabine alone (X)
(all 80% of full dose and unblinded). The primary end point was patient recruitment over an 18-month period. A registration study
recorded treatment choice for all patients with advanced GO cancer at trial centres.
Results: A total of 313 patients were considered for palliative chemotherapy for GO cancer over the 18-month period: 115
received full dose treatment, 89 less than standard treatment or entered 321GO and 111 no treatment. Within 321GO, 55 patients
were randomly assigned (19 to OX and X; 17 to EOX). Progression-free survival (PFS) for all patients was 4.4 months and by arm 5.4,
5.6 and 3.0 months for EOX, OX and X, respectively. The number of patients with a good overall treatment utility (OTU), a novel
patient-centred endpoint, at 12 weeks was 3 (18%), 6 (32%) and 1 (6%) for EOX, OX and X, respectively. At 6 weeks, 22 patients
(41%) had experienced a non-haematologic toxicityXgrade 3, most commonly lethargy or diarrhoea. The OTU was prognostic for
overall survival in patients alive at week 12 (logrank test P¼ 0.0001).
Conclusions: It is feasible to recruit elderly and/or frail patients with advanced GO cancer to a randomised clinical trial. The OX is
the preferred regimen for further study. Overall treatment utility shows promise as a comparator between treatment regimens for
feasibility and randomised trials in the elderly and/or frail GO cancer population.
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Patients with gastroesophageal (GO) cancer are often frail because
of comorbidities and malnourishment. Gastric and oesophageal
cancers are largely diseases of the elderly, especially gastric cancer
where 77% of patients are diagnosed over the age of 75 years
(Shitara et al, 2009). However, there is a conspicuous mismatch
between the age and fitness of patients with advanced GO cancer
and that of participants in practice defining randomised controlled
trials (RCTs; Trumper et al, 2006, 2006; Cunningham et al, 2008).
Response rates to chemotherapy are unaffected by age but
comorbid and age-related changes in pharmacokinetics and
pharmacodynamics can lead to increased toxicity with doses
established in younger patients (Stein et al, 1995; Popescu et al,
1999; Sargent et al, 2001). Hence, an evidence base is needed that
addresses treatment choices in the frail and elderly GO cancer
population.
In 2008, a regional audit and a national survey in the United
Kingdom identified widely varying practice and no standard
regimen or dosing strategy in the use of chemotherapy in this
patient population. Triple-, double- or single-agent regimens were
in use, largely reflecting modifications of standard regimens used at
full dose in fitter patients. Three-, two- or one-drug chemotherapy
for advanced GO cancer (321GO) is a phase two RCT designed to
assess the feasibility of a subsequent phase three RCT that may
include diverse chemotherapy treatments in the elderly and/or frail
advanced GO cancer population.
MATERIALS AND METHODS
The 321GO had several novel design features embedded within it.
This included an encompassing registration study that captured all
patients presenting to the participating cancer networks with
advanced GO cancer, the proportion considered for chemotherapy
for advanced GO cancer and the proportion randomised into
321GO. Secondly, a comprehensive assessment of tolerability,
quality of life, patient acceptability, patient symptoms and
nutrition was undertaken at baseline and weeks 12 and 24 in
order to determine (1) whether such an assessment was feasible
and (2) best identify which chemotherapy treatment regimens
would be used in a phase three trial. Overall treatment utility
(OTU), a novel patient-centred composite end point, was also
assessed as a tool to discriminate between treatment regimens in
this population.
The 321GO trial took place in six UK centres across two Cancer
Research Networks, recruiting patients between June 2009 and
January 2011. A key eligibility criterion stated that the patient
should not be considered a candidate for standard full-dose
three-drug chemotherapy regimens. Patients were required to be
considered by the treating clinician to be fit and suitable for
reduced-dose chemotherapy. Other eligibility criteria included a
requirement for histologically confirmed carcinoma of the
oesophagus, gastroesophageal junction or stomach of either
squamous, adenocarcinoma or undifferentiated type and planned
for treatment with palliative intent. Patients were required to be
over the age of 18 years but there was no upper age limit. Patients
were excluded if they had previously received chemotherapy for
gastric or oesophageal cancer; had another malignancy that in the
opinion of the treating consultant would potentially impede
interpretation of the outcome of 321GO therapy; had treatment
with another investigational agent within 30 days of commencing
treatment; and had previously been treated with anthracyclines to a
total cumulative dose of epirubicin of 900mgm 2 (or equivalent)
including the treatment to be administered within this trial.
Patients were not excluded for a medical condition unless this
impaired their ability to consent or was so severe as to preclude
protocol treatment. Minimum organ function required an esti-
mated glomerular filtration rate of 430mlmin 1, bilirubin less
than three times the upper limit of normal (ULN), transaminases
less than five times ULN, neutrophils41.5 109/l, white cell count
43 109/l and platelets 4100 109/l. Current uncontrolled
cardiac impairment was also an exclusion criterion.
We obtained written consent after verbal explanation and a
written information sheet had been given to the patient, with at
least 24 h allowed for consideration. Thereafter, but before
randomisation, a 128-item comprehensive health assessment
(CHA) was carried out (Supplementary Appendix). This assess-
ment comprised three nurse-administered modules (including
physical parameters, nutrition and medical comorbidity) and five
patient-completed modules (including activities of daily living,
symptoms, quality of life and medical resource use; Charlson et al,
1987; Nouri and Lincoln, 1987; Aaronson et al, 1993; Kind,
1996; Guigoz and Vellas, 1997; Simonsick et al, 2000; Lagergren
et al, 2007).
The 321GO was approved by the NHS National Research Ethics
Service, Sponsored by the University of Leeds and conducted by
the University of Leeds Clinical Trials Research Unit and St James
Institute of Oncology. The study was registered: ISCTRN33934807.
Study design. Patients were randomly assigned in a 1 : 1 : 1 ratio
using a central telephone randomisation service. Stratified
permuted block randomisation was used with the stratification
factors age (p75 vs 475 years) and the presence of distant
metastases (yes vs no). Treatment allocation was not masked. In
addition to those patients randomised, a detailed screening log was
maintained in order to capture the number of patients in each
region with a diagnosis of GO cancer, the proportion of these
patients considered fit for full-dose chemotherapy, the proportion
randomised into 321GO or treated with reduced dose non-
standard chemotherapy and those not treated with any
chemotherapy.
Procedures. Trial regimens (at 80% of full dose) were EOX:
epirubicin 40mgm 2 i.v. bolus and oxaliplatin 104mgm 2 i.v.
infusion over 2 h and capecitabine 500mgm 2 b.d. on days 1–21,
repeated every 21 days. The OX was identical to EOX other than
the omission of epirubicin. The X was capecitabine 1000mgm 2
b.d. on days 1–14 only of a cycle repeated every 21 days.
Before each cycle, toxicity was scored with Common Terminol-
ogy Criteria for Adverse Events version 3.0 (CTCAEv3). Detailed
management of side effects was specified; briefly, grade one and
worse effects were treated symptomatically; persisting grade two
and worse toxicity at day 1 of the next treatment cycle incurred
a 1-week delay. Cytotoxic doses were reduced by 25% after two
delays, or one delay of X2 weeks. Compliance with capecitabine
was assessed with patient diary cards and tablet returns.
At 6 weeks, doses could be escalated to 100% of standard doses
provided that no grade two or worse non-haematological toxic
effects had occurred and that the patient consented. After week 12,
radiological response was assessed with Response Evaluation
Criteria in Solid Tumours (RECIST v1.1) criteria; the clinician
assessed whether there had been clinical deterioration in the
patient and the CHA was repeated. Thereafter, patients without
radiological or clinical evidence of deterioration could continue the
same regimen for up to 12 further weeks (four further cycles).
Please see Supplementary Appendix for full trial protocol.
Statistical analysis. The primary outcome measure to determine
feasibility was the rate of recruitment achievable over 18 months in
two UK cancer networks. For a national phase three trial planned
as a non-inferiority trial, using a non-inferiority margin of
a 1-month reduction in median PFS between any two of the three
regimens, with 80% power at the one-sided 5% significance level,
720 patients would be needed. The Yorkshire and Humber cancer
networks have a combined population of 3.5M, representing 5.7%
of the UK population, and hence making the assumption that
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recruitment locally would be twice that of elsewhere given ‘local
interest’, accrual of over 45 patients in 18 months would suggest a
national study could recruit 750 patients over 3 years. Additionally,
data were collected for the number of patients at each participating
network considered for or denied palliative chemotherapy for
advanced GO cancer, and the proportion randomised into 321GO.
Secondary outcomes sought to describe tolerability of the
regimens and included: the incidence of CTCAEv3 grade Xthree
non-haematological toxicities at 6 weeks, the incidence of SAEs
and dose delays/reductions, the ability/willingness to dose escalate
to 100% at week 6, patient acceptability scores, quality of life and
nutritional and symptom changes.
Progression-free survival (PFS) and overall survival (OS) were
also pre-specified as descriptors to enable informed sample size
calculations for a subsequent phase three trial.
This novel design for a feasibility study embedded within it an
OTU assessment, a patient-centred tool that was first used within
the FOCUS2 trial that examined chemotherapy options in a frail
and elderly colorectal cancer population. As a composite end point,
it was found to be better able to discriminate between different
regimens than more conventional end points such as PFS
(Seymour et al, 2011). The OTU was scored at 12 weeks. Good
OTU was defined as no clinical or radiological evidence of disease
progression, and no major negative treatment effects in terms of
toxicity or patient acceptability. Intermediate OTU signified either
clinical deterioration but no negative treatment effect, or a
significant negative treatment effect but no clinical deterioration.
Poor OTU indicated both clinical deterioration and a major
negative treatment effect, or death. The patient acceptability score
was determined by the response to two questions, ‘How much has
your treatment interfered with daily activities?’ and ‘How
worthwhile has your treatment been?’ the options being not ‘very
much’ or ‘very much’ and not ‘not at all’ or ‘not at all’.
RESULTS
In total, over the 18-month study period, 313 patients with
advanced GO cancer were discussed at participating multi-
disciplinary team meetings of which 115 (36%) received standard
treatment (EOX at full dose), 89 (28%) patients less than standard
treatment and 111 (36%) no treatment. Of the patients receiving
less than standard treatment, 55 patients were recruited to 321GO
representing an accrual rate of three patients per month. For those
patients who did not enter the study but received non-standard
chemotherapy, the majority, 29 patients (85%), received either
three- or two-drug chemotherapy regimens (Figure 1). Median age
was 75 years (range 50–87). Six (11%) patients had a WHO
performance status (PS) of 0, 31 (56%) had a PS of one and 18
(33%) had a PS of two (Table 1).The main reasons stated by
investigators for entry into 321GO were borderline performance
status (40%), general medical comorbidity (40%) and advanced age
(64%; Table 2).
In addition, 44 (80%) patients were still receiving treatment at 6
weeks and hence were eligible for dose escalation to standard
doses. Of these, 10 (23%) had a dose escalation, although none of
these patients maintained this escalation in dose past cycle four.
Then, 43 (80%) patients stopped treatment before completing all 8
cycles of treatment. In addition, 10 (19%) had a dose reduction
either at cycle two or three because of toxicity. At the 6-week
assessment, 22 patients (41%) had experienced a grade three non-
haematologic or greater toxicity or serious adverse event, the most
common toxicities at grade three or worse being lethargy and
diarrhoea (Table 3).
Overall, median PFS was 4.4 months (Figure 2A). By arm,
median PFS was 5.4, 5.6 and 3.0 months for patients receiving
EOX, OX and X, respectively (Figure 2B). Median overall survival
was 7.1 months (Figure 2C). By arm, median OS was 8.1, 9.5 and
3.6 months for patients receiving EOX, OX and X, respectively
(Figure 2D). At 12 weeks, the RECIST response rate for all patients
313 Patients considered for palliative chemotherapy
for GO cancer through participating MDTs 
115 (36%) full-dose
treatment or REAL 3
89 (28%) less than
standard treatment
111 (36%) no
treatment
55 (62%) entered
321GO
34 (38%) non-
trial
13 (38%) 3-drug
chemotherapy
17 (30%) EOX
(80% dose)
After 6 weeks: consider increase to 100% dose if no grade  2 toxicity
Re-evaluate at 12 weeks: objective response; symptomatic
response; LHA (limited health/QoL reassessment)
19 (35%) OX
(80% dose)
19 (35%) X
(80% dose)
16 (47%) 2-drug
chemotherapy
5 (15%) 1-drug
chemotherapy
Figure 1. Trial flowchart and decision pathway for patients considered
for palliative chemotherapy for advanced GO cancer.
Table 1. Patient characteristics
EOX
(n¼17)
OX
(n¼19)
X
(n¼19)
Total
(n¼55)
Sex
Men 13 (76%) 13 (68%) 15 (79%) 41 (75%)
Women 4 (24%) 6 (32%) 4 (21%) 14 (25%)
Age (years)
Median 74 77 75 75
IQR 70–77 70–79 70–78 70–78
Range 64–82 50–85 57–87 50–87
WHO performance status
0 0 (0%) 4 (21%) 2 (11%) 6 (11%)
1 11 (65%) 10 (53%) 10 (53%) 31 (56%)
2 6 (35%) 5 (26%) 7 (37%) 18 (33%)
Primary tumour site
Oesophagus 5 (29%) 11 (58%) 8 (42%) 24 (44%)
Gastroesophageal junction 2 (12%) 1 (5%) 4 (21%) 9 (16%)
Gastric 10 (59%) 5 (26%) 7 (37%) 22 (40%)
Unknown 0 (0%) 1 (5%) 0 (0%) 1 (2%)
Metastases
Yes 17 (100%) 17 (89%) 18 (95%) 52 (95%)
No 0 (0%) 2 (11%) 1 (5%) 3 (5%)
Histology
Squamous cell carcinoma 2 (12%) 3 (16%) 1 (5%) 6 (11%)
Adenocarcinoma 15 (88%) 15 (79%) 18 (95%) 48 (87%)
Mixed squamousþ adenocarcinoma 0 (0%) 1 (5%) 0 (0%) 1 (2%)
Abbreviations: EOX¼epirubicin, oxaliplatin and capecitabine; IQR¼ interquartile range;
OX¼oxaliplatin and capecitabine; WHO¼World Health Organisation; X¼ capecitabine.
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was (complete responseþ partial response) 30% and there
was evidence of disease control (complete responseþ partial
responseþ stable disease) in 54% of patients (Table 4). At 12
weeks, the mean global QoL score, adjusted for baseline values, was
67.8, 70.3 and 64.8 for patients receiving EOX, OX and X. Mean
fatigue score was 31.7, 25.6 and 42.6, respectively (Table 4).
Although not a pre-determined end point in this study, the
feasibility of using OTU as an outcome measure was assessed in
view of the proposed use of OTU as an outcome measure in a
phase three trial for this population. The percentage of patients
with a good OTU was 18%, 32% and 17% with EOX, OX and X,
and was 19% overall. The OTU was prognostic for OS in patients
alive at week 12 (logrank test for trend P¼ 0.0001) and PFS in
patients alive and progression free at week 12 (logrank test for
trend P¼ 0.0001). Of note, radiological response (RECIST) was
less prognostic for OS (logrank test for trend P¼ 0.40).
DISCUSSION
There is a growing need for RCTs targeted at the elderly and frail
cancer population and this prompts the evaluation of new
feasibility and late phase trial designs that fit the specific needs
of this group. Feasibility studies are usually designed to determine
the practicality of randomising the population in question, the
sample size needed for the main study and sometimes to help
decide the outcome measure. Such studies may not be reported in
the peer-reviewed literature and there is a need for an ongoing
discussion as to best practice with regard to design (Arain et al,
2010) The 321GO incorporated novel elements to determine late
phase feasibility. Firstly, besides making an assessment of
recruitment rate, data to determine the proportional recruitment
from all patients considered for chemotherapy were collected.
Secondly, data were collected with regard to global patient benefit.
Given that survival benefits may be more limited in this vulnerable
group, we believe an early assessment of QoL as an outcome
measure is important to aid phase three design.
This trial demonstrates that elderly and frail patients with
advanced GO cancer can be randomised into a clinical trial and
undergo complex assessment of clinical benefit. The registry
study showed that almost half of those patients who received
chemotherapy received less than full-dose treatment and hence
confirms that this is a substantial patient group, supporting the
need for an evidence base. The population recruited to 321GO
(median age of 75 years and PS2 in 33% of cases) had very different
baseline characteristics compared with the recent REAL2 and
REAL3 trials (median age, 61–65 (dependent on arm) years and
62–63 years; PS2 8.5–12.4% and 5–6% of patients, respectively)
(Cunningham et al, 2008; Waddell et al, 2013). The recruitment
rate of three patients per month within the Yorkshire Cancer
Network is consistent with the number needed to appropriately
power a national phase three trial.
The use of OTU as a more patient-centred approach in assessing
benefit from cancer therapy was first explored in the FOCUS2 trial
in which OTU demonstrated unequivocal benefit from oxaliplatin
chemotherapy in elderly and frail patients with advanced colorectal
cancer when other more standard endpoints were divergent
(Seymour et al, 2011). In 321GO, OTU was found to be useful
in comparing regimens to take through to a phase three trial and
indeed was more prognostic for OS than the more standard end
point, radiological response. There was good compliance with
regard to completing the baseline CHA and hence this may have
potential as a tool to discriminate between patients who are more
likely to benefit from chemotherapy and those not (Table 5).
In reporting the results of 321GO we have deliberately avoided
reporting some of the standard outcomes seen in standard phase II
trials. Specifically, we have omitted a full breakdown of low-grade
toxicities, instead relying on tolerability metrics and assessments of
quality of life and functional outcomes as better reflecting the
impact on patients.
In the FOCUS2 trial, 37% of patients had a dose escalation to
100% of standard doses, although only 14% (of all patients who
had started treatment) sustained this higher dose to 12 weeks.
Within 321GO, none of the patients who had a dose escalation
after two cycles maintained this past cycle four, and hence this does
not seem to be a sensible strategy in frail and elderly patients with
advanced GO cancer.
Table 2. Reasons given by investigators for trial participation
EOX
(n¼17)
OX
(n¼19)
X
(n¼19)
Total
(n¼55)
Borderline performance status
Yes 8 (47%) 6 (32%) 8 (42%) 22 (40%)
No 9 (53%) 13 (68%) 11 (58%) 33 (60%)
General medical comorbidity
Yes 8 (47%) 7 (37%) 7 (37%) 22 (40%)
No 9 (53%) 12 (63%) 12 (63%) 33 (60%)
Borderline renal or hepatic function
Yes 3 (18%) 2 (11%) 1 (5%) 6 (11%)
No 14 (82%) 17 (89%) 18 (95%) 49 (89%)
Advanced age
Yes 9 (53%) 13 (68%) 13 (68%) 35 (64%)
No 8 (47%) 6 (32%) 6 (32%) 20 (36%)
Other reason
Yes 1 (6%) 0 (0%) 1 (5%) 2 (4%)
No 16 (94%) 19 (100%) 18 (95%) 53 (96%)
Abbreviations: EOX¼ epirubicin, oxaliplatin and capecitabine; OX¼oxaliplatin and
capecitabine; X¼ capecitabine. Other reasons reported: ‘not fit for full-dose chemotherapy’
(X); ‘clinician decision’ (EOX).
Table 3. Tolerability
EOX
(n¼17)
OX
(n¼19) X (n¼19)
Total
(n¼55)
Grade 3þ non-haematological toxicities (at 6-week assessment)
Any toxicity or SAR 8 (47%) 7 (37%) 7 (39%) 22 (41%)
Nausea 2 (12%) 0 (0%) 0 (0%) 2 (4%)
Vomiting 1 (6%) 1 (5%) 0 (0%) 2 (4%)
Anorexia 1 (6%) 0 (0%) 0 (0%) 1 (2%)
Stomatitis 0 (0%) 0 (0%) 1 (6%) 1 (2%)
Diarrhoea 2 (12%) 0 (0%) 2 (11%) 4 (7%)
Lethargy 4 (24%) 2 (11%) 1 (6%) 7 (13%)
Peripheral neuropathy 0 (0%) 1 (5%) 0 (0%) 1 (2%)
Hand and foot syndrome 0 (0%) 0 (0%) 1 (6%) 1 (2%)
Other 4 (24%) 3 (16%) 3 (17%) 10 (19%)
Treatment delay (at cycles 2 or 3)
Yes 5 (29%) 2 (11%) 2 (11%) 9 (17%)
No 12 (71%) 17 (89%) 16 (89%) 45 (83%)
Dose reduction (at cycles 2 or 3)
Yes 4 (24%) 3 (16%) 3 (17%) 10 (19%)
No 13 (76%) 16 (84%) 15 (83%) 44 (81%)
Treatment stopped at any time during trial
Yes 13 (76%) 16 (84%) 14 (78%) 43 (80%)
No 4 (24%) 3 (16%) 4 (22%) 11 (20%)
Dose escalation (at 6-week assessment)
Yes 2 (12%) 3 (16%) 5 (28%) 10 (19%)
No 15 (88%) 16 (84%) 13 (72%) 44 (81%)
Abbreviations: EOX¼ epirubicin, oxaliplatin and capecitabine; OX¼oxaliplatin and
capecitabine; SAR¼ serious adverse reaction; X¼ capecitabine.
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Figure 2. Survival curves. (A) Kaplan–Meier estimate of progression-free survival for all patients in the study, (B) Kaplan–Meier estimates of
progression-free survival for each arm, (C) Kaplan–Meier estimate of overall survival for all patients in the study and (D) Kaplan–Meier estimate of
overall survival for each arm.
Table 4. Outcome measures
EOX (n¼17) OX (n¼19) X (n¼19) Total (n¼55)
Median PFS (months; 95% CI) 5.4 (2.3–11.7) 5.6 (2.7–8.7) 3.0 (2.4–4.1) 4.4 (2.8–5.6)
Median OS (months; 95% CI) 8.1 (2.3–11.7) 9.5 (5.0–NR) 3.6 (2.4–8.1) 7.1 (4.3–10.1)
RECIST response at week 12
Response rate CRþPR 5 (29%) 9 (47%) 2 (11%) 16 (30%)
Disease control CRþPRþSD 10 (59%) 11 (58%) 8 (44%) 29 (54%)
OTU score at week 12
Good 3 (18%) 6 (32%) 1 (6%) 10 (19%)
Intermediate 4 (24%) 4 (21%) 4 (22%) 12 (22%)
Poor 8 (47%) 6 (32%) 10 (56%) 24 (44%)
Missing 2 (12%) 3 (16%) 3 (17%) 8 (15%)
Patient acceptability scores
Category Ag 3 (18%) 6 (32%) 3 (17%) 12 (22%)
Category BZ 7 (41%) 9 (47%) 6 (33%) 22 (41%)
Died before assessment 5 (29%) 1 (5%) 6 (33%) 12 (22%)
Missing 2 (12%) 3 (16%) 3 (17%) 8 (15%)
QLQ-C30 scores at week 12
Mean global QoL score at 12 weeksa 67.8 (CI 54.5–81.2) 70.3 (CI 58.3–82.3) 64.8 (CI 51.5–78.2) 67.0 (CI 60.1–73.8)
Mean fatigue score at 12 weeksa 31.7 (CI 18.4–45.1) 25.6 (CI 14.3–37.0) 42.6 (CI 29.3–55.8) 32.9 (CI 25.9–40.0)
Mini-nutritional assessment
Mean global MNA score at week 12a b 24.2 (CI 22.3–26.2) 25.8 (CI 21.0–30.6) 24.2 (CI 22.5–25.9)
Nottingham ADL at week 12
Mean global NADL score at 12 weeksa 13.4 (CI 11.4–15.3) 14.8 (CI 13.0–16.5) 14.3 (CI 12.4–16.3) 14.2 (CI 13.2–15.2)
Physical tests at week 12
Mean weight at 12 weeksa 65.8 (CI 62.1–69.4) 69.3 (CI 66.7–71.9) 67.4 (CI 64.5–70.3) 67.6 (CI 65.9–69.3)
Mean arm circumference at 12 weeksa 24.5 (CI 23.1–26.0) 25.5 (CI 24.2–26.8) 23.3 (CI 21.8–24.8) 24.4 (CI 23.6–25.2)
Abbreviations: ADL¼Activities of Daily Living; CI¼ 95% confidence interval; CR¼ complete response; EOX¼ epirubicin, oxaliplatin and capecitabine; MNA¼Mini-nutritional assessment;
NADL¼Nottingham Activities of Daily Living; NR = not reached; OS¼overall survival; OTU¼overall treatment utility; OX¼oxaliplatin and capecitabine; PFS¼progression-free survival;
PR¼partial response; QoL¼quality of life; RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼ stable disease; X¼ capecitabine. (%)¼Percentage of patients who attended visit. The
symbol ‘%’ indicates the percentage of patients in the trial or trial arm.
aAdjusted for baseline score and repeated measures.
bNo patient fully completed the 12-week mini-nutritional assessment in the EOX group.
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A median PFS of 4.4 months and OS of 7.1 months was less
than comparator studies using standard doses of chemotherapy
consistent with this frailer population (Cunningham et al, 2010).
However, for a cohort of patients, overall QoL improved with
treatment. The question remains open as to whether palliative
chemotherapy for this group of patients is of benefit and if so
which chemotherapy regimens are most likely to provide clinical
benefit. Given the poorer PFS, OS and OTU scores for EOX vs OX,
this study questions the value of anthracyclines as part of
combination chemotherapy for advanced gastroesophageal cancer.
Recent evidence in both the adjuvant and advanced setting has also
suggested that anthracyclines may add little in the treatment of
gastroesophageal cancer (Guimbaud et al, 2014; Alderson et al,
2015).
A phase three trial has been demonstrated as feasible and is
now required to definitively provide an evidence base to guide the
treatment of patients who are frail or elderly with advanced
gastric and oesophageal cancer. Although the results of 321GO
could be interpreted as favouring a doublet regimen over single
agent or triplet chemotherapy, it remains to be determined
whether the OX regimen used represents an overdosing or
underdosing for the specific patients groups included in the
trial. In an attempt to answer this question, based on the success
of 321GO, the phase three trial GO2 recently commenced
recruitment across 56 sites in the United Kingdom to determine
the optimal dose intensity of OX in this patient population.
Further information about GO2 is available via weblink http://
www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-
looking-at-chemotherapy-for-people-with-advanced-cancer-of-the-
stomach-or-food-pipe-go2. We also recommend that further
research beyond the 321GO and GO2 programme should
consider alternative agents such as S1 or targeted therapies as
they emerge from research pipelines.
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